Clinical efifcacy and safety of decapeptide-12 in the treatment of melasma
Abstract：Objective To investigate the efifcacy and safety of lumixylTM (decapeptide-12) for melasma therapy. Methods Total 30 volunteers with melasma were enrolled in this study by self-control before and after the treatment. Subjects received a total of lumixylTM daily for 6 to 8 weeks, and then the efifcacy at 1 month and 3 months after the treatment were evaluated by digital photography and VISIA by both the doctors and volunteers, followed up for 6 months. Results From the baseline to to 3 months after of treatment, 5 case recovered (16.7%), signiifcant improvement 14 case (46.7%), slight improvement 7 case (23.3%), no change 4 case (13.3%). The total efifciency was 86.7%. There was a signiifcant statistical difference between before and after the treatment (P<0.05). Follow-up 6 months, 5 cases (16.7%) had mild relapse. Over 60%subjects considered satisfactory or very satisfactory after the course of treatment. No signiifcant adverse reactions occurred. Conclusion LumixylTM is safe and effective in the treatment of melasma in Chinese.
Keywords：MelasmaLumixylTMClinical efifcacy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 263-265 )